COM902 is one of only two clinical-stage Fc-reduced anti-TIGIT monoclonal antibodies currently in clinical development and importantly it’s fully owned by Compugen.
COM902 is a therapeutic antibody against the immuno-oncology target TIGIT, a recently validated immune checkpoint. Compugen is ultimately developing COM902 to broaden the clinical potential of its PVRIG inhibitor, COM701 allowing to comprehensively block the DNAM axis by the parallel inhibition of TIGIT and PVRIG. With wholly owned candidates targeting two of the three pathways involved in its triple pathway hypothesis, both PVRIG and TIGIT, Compugen is able to maximally control its clinical strategy. Read more about COM701, PVRIG and Compugen’s triple pathway hypothesis of anti-tumor response here.
TIGIT, discovered by Compugen (and others) in 2009 using its computational discovery platform, and PVRIG are distinct but complementary pathways in the DNAM axis considered to modulate immune cell responses to tumors. Preclinical data indicate that treatment with COM902 enhances T cell activation and increases anti-tumor immune responses. Additional preclinical data show a synergistic effect of COM902 and other checkpoint inhibitors such as COM701 and/or PD-1 inhibitors.